Skip to content

OnyxBiotech News

Subscribe About Onyx
Cell & Gene Leaders Live Sunday 15 November 2026 · The Shard (Shangri-La), London · One-day summit for cell & gene therapy leaders Sunday 15 November 2026 · The Shard (Shangri-La), London Get tickets → London Life Sciences Week Guide The unofficial London Life Sciences Week Guide, published by Onyx Newsroom · Every event 15–19 November 2026 Every event 15–19 November 2026 · Published by Onyx Newsroom Plan your week →
Live Interviews Editor's pick

Fabian Gerlinghaus, CEO, Cellares | Onyx Live | JPM 2026

The platform built to cut CAR-T manufacturing costs by ~50% is about to power its first patient dosing.

Dr. Adil Ali
Published
1 min read

When Onyx caught up with CEO Fabian Gerlinghaus at JPM 2026, we'd just heard groundbreaking news.

Cabaletta Bio’s investigational CAR T cell therapy 'rese-cel' had received FDA clearance of an IND Amendment to use Cellares’ Cell Shuttle platform for manufacturing.

Please sign-up to continue reading

Subscribe

Be the first to receive exclusive interviews with cutting-edge biotech and pharma CEOs, straight to your inbox. Unsubscribe at any time. Already have an account? Sign In

Coming up: Cell & Gene Leaders Live, Sun 15 Nov at The Shard · London Life Sciences Week Guide, 15–19 Nov 2026 ·

More Live Interviews ↗